DCND is committed to furthering science and medicine to help patients. Getting involved in research can help the medical community develop new drugs and treatments that can help improve the quality of life for patients. The overall goal is to know as much as we can about a disease so we can better treat it. By getting involved in research, you can help others in the same situation and possibly get access to cutting edge treatment not available to the public yet.
Now enrolling in studies for:
- Multiple Sclerosis
Are you a candidate?
How research works
Our research team and your provider will determine what study best lines up with your diagnosis. Our team will review the research study in detail with you and your participation is completely voluntary. Some studies reimburse you for travel. Every study is different on what kind of information or exam is required.
RethinkALZ & RefocusALZ
To be considered for the RethinkALZ study or RefocusALZ trials, patients must:
- Be ages 50 to 87 years old
- Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
- Have a gradual change in memory for six months or more
- Have a family member or loved one who can be available as a study partner during the entire study
- Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection
More info: https://rethink-alz.com/index.html
PASS. ≥18 y.o. Starting or switching to new preventive migraine treatment
TRIUMPH. ≥18 y.o. starting or switching to new preventive migraine treatment. More information here
CORRONA MS REGISTRY. All MS patients ≥18 years old who are NOT currently enrolled in clinical trials.
VERISMO. New starts (within 30 days) of ANY disease modifying therapy for MS.
CLICK-MS. Relapsing Remitting Multiple Sclerosis. ≥ 18 years old; Previously on oral or injectable MS medication, starting Mavenclad.
MASTER-2. Relapsing Remitting Multiple Sclerosis. ≥ 18 years old; Previously on IV MS medication, starting Mavenclad
GEMINI-2. Relapsing Remitting Multiple Sclerosis. 18-55 years old; with documented relapse or new brain lesion in MRI within the previous year.
TEMPO-1. Age 40-80 y.o. not yet started on Parkinson’s medication. Willing to take a partial agonist of D1 receptor
ALS Registry- All patients who have been diagnosed with ALS.
Neurogenic Orthostatic Hypotension
RESTORE. ≥18 years old; experiencing dizziness/lightheadedness upon standing associated with Primary Autonomic Failure (PD, MSA or PAF) or NDAN or DBH Deficiency.
Talk with our research team
ARE YOU A CANDIDATE? FIND OUT NOW.